Planned Parenthood Mar Monte, INC.
Planned Parenthood Mar Monte, INC. was paid $5.02M by Medicaid between Jan 2018 and Dec 2024, across 47 billing codes. Its largest line is J7307, Etonogestrel (contraceptive) implant system, including implant and supplies — 13% of everything it billed.
HAYWARD, CA 94541
Next to other Clinic Pharmacy providers in California
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,214 | $843K | |
| 2019 | 16,997 | $731K | |
| 2020 | 11,993 | $559K | |
| 2021 | 14,517 | $814K | |
| 2022 | 10,297 | $536K | |
| 2023 | 13,444 | $680K | |
| 2024incomplete | 17,235 | $852K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 13% | 811 | 806 | $646K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 11% | 4,755 | 4,628 | $574K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 6,636 | 6,370 | $561K |
| J3490 | Unclassified drugs | 7.2% | 10,172 | 8,631 | $362K |
| S4993 | Contraceptive pills for birth control | 6.5% | 3,114 | 3,084 | $324K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 6.1% | 2,545 | 2,539 | $304K |
| S0199 | Medically induced abortion by oral ingestion of medication including all associated services and supplies (e.g., patient counseling, office visits, confirmation of pregnancy by hcg, ultrasound to confirm duration of pregnancy, ultrasound to confirm completion of abortion) except drugs | 5.8% | 788 | 782 | $293K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.0% | 4,244 | 4,177 | $252K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 4.0% | 6,639 | 6,279 | $201K |
| 87806 | 3.9% | 9,227 | 7,970 | $194K | |
| J7304 | Contraceptive supply, hormone containing patch, each | 3.5% | 230 | 229 | $178K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.4% | 862 | 861 | $172K |
35 more codes
| 11981 | 3.1% | 728 | $154K | |
| 99204 | Doctor's office visit, new patient (more involved) | 2.5% | 559 | $125K |
| 58300 | 2.1% | 1,093 | $106K | |
| 99201 | 2.1% | 1,186 | $105K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.0% | 2,040 | $50K |
| 99401 | <1% | 2,269 | $43K | |
| 11976 | <1% | 587 | $32K | |
| 99402 | <1% | 1,003 | $32K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 713 | $31K |
| S0190 | Mifepristone, oral, 200 mg | <1% | 498 | $28K |
| A4267 | Contraceptive supply, condom, male, each | <1% | 3,162 | $28K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 43 | $26K |
| 58301 | <1% | 770 | $23K | |
| S5000 | Prescription drug, generic | <1% | 3,065 | $22K |
| J7300 | Intrauterine copper contraceptive (paragard) | <1% | 25 | $21K |
| 99000 | <1% | 5,628 | $20K | |
| 83986 | <1% | 7,291 | $18K | |
| 81025 | <1% | 7,275 | $18K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 5,375 | $16K |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 1,057 | $13K |
| J7303 | Contraceptive supply, hormone containing vaginal ring, each | <1% | 39 | $11K |
| Q3014 | Telehealth originating site facility fee | <1% | 398 | $8K |
| 99070 | <1% | 1,096 | $7K | |
| 11982 | <1% | 104 | $5K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 835 | $4K |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 305 | $3K |
| S0191 | Misoprostol, oral, 200 mcg | <1% | 840 | $2K |
| 81002 | <1% | 1,148 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 109 | $723.34 |
| 85018 | <1% | 458 | $713.33 | |
| T1014 | Telehealth transmission, per minute, professional services bill separately | <1% | 398 | $632.97 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 16 | $150.03 |
| 86901 | <1% | 85 | $130.29 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 238 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 238 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.